Stock Analysis
Incyte Genomics IncINCY
P/E 14.21×· 5Y range 13.32–663.64×· bottom 4% of history
Sector: Healthcare · Industry: Services-Commercial Physical & Biological Research
AnalystsBuy35 analystsP/E 14.2× sits at the 4th percentile of its 5.086926762491444-year history.
Cash covers 11853% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Profitability100
- Financial Health100
Risks
- Quality37
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓Altman Z 10.9 — safe-zone balance sheet
- ✓ROE 25.4% — efficient capital deployment
- ✓Revenue CAGR 14.5% — durable top-line growth
- ✓Interest coverage 213.7× — debt well covered
What's happening with INCY
Profile
Strong profitability, financial health and valuation; earnings quality and moat lag behind.
How is each axis scored?
- Valuation90/100 · Strong
- P/E vs own history (4th pct)25/25
- FCF yield (8.4%)25/25
- P/S (3.9x)20/25
- EV/EBIT (10.4x)20/25
- Growth52/100 · Moderate
- Revenue CAGR (14.5%)20/25
- Net income CAGR (7.9%)12/25
- EPS CAGR 5Y (10.7%)20/25
- Fwd implied growth (-18.2%)0/25
- Profitability100/100 · Strong
- ROIC (76.1%)25/25
- ROE (25.4%)25/25
- Net margin (27.7%)25/25
- Operating margin (30.6%)25/25
- Financial Health100/100 · Strong
- Altman Z (10.93)25/25
- Current ratio (4.59)25/25
- Interest coverage (213.7x)25/25
- Net cash / debt (Net cash)25/25
- Quality37/100 · Weak
- Piotroski F (8/9)25/25
- Beneish M (-2.21)12/25
- FCF conversion (n/a)0/25
- Margin stability (σ 25.8%)0/25
- Moat48/100 · Weak
- ROIC >12% years (6/9 yrs)13/25
- Median gross margin (94.7%)25/25
- FCF-positive years (5/7 yrs)10/25
- Worst-year net margin (worst -20.4%)0/25
Risk Flags
- ⚠2 loss-making years in recent history
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. Show more
The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Headquarters: WILMINGTON, DE · Employees: 2,844 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
90A+P/E (TTM)14.2xA
Grade A: CheapPrice / TTM EPS (own statements) — vs own 5Y history: 13.3x–663.6x · 4th pct
P/FCF12.0xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield8.4%A
Grade A: ValueLatest stored TTM FCF / Market Cap — vs own 5Y history: -2.2%–8.7% · 99th pct
P/S (TTM)3.94xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.5x–6.2x · 42nd pct
EV/EBIT10.4xA
Grade A: CheapEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 9.7x–12.6x · 16th pct
EV/Sales3.3xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E17.4xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.61xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.09B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
100A+ROIC76.1%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE25.4%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA22.6%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin27.7%A
Grade A: HighNet Income / Revenue
Operating Margin30.6%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin92.6%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
52CRevenue CAGR14.5%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR7.9%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)10.7%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth-18.2%D
Grade D: Decl.Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income15.8%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.4%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
100A+Altman Z-Score10.93A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.59xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio4.31xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage213.7xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.01xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt118.53xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
37DPiotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.21C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability25.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.82xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Heeson Lee Filed | Heeson Lee | Tax withholding | -463 | |
Clancy Paul J Filed | Clancy Paul J | Grant / award | +203 | |
HARRIGAN EDMUND Filed | HARRIGAN EDMUND | Grant / award | +206 | |
BAKER BROS. ADVISORS LP Filed | BAKER BROS. ADVISORS LP | Grant / award | +322 | |
Gardner David H Filed | Gardner David H | Tax withholding | -920 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
CAGNONI PABLO J Filed | CAGNONI PABLO J | Option exercise | -9233 | |
CAGNONI PABLO J Filed | CAGNONI PABLO J | Option exercise | -6477 | |
CAGNONI PABLO J Filed | CAGNONI PABLO J | Option exercise | -4551 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
48D+ROIC >12% Years6/9 yrsC
Grade C: ModerateShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)94.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years5/7 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-20.4%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$7.95
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$22.57
Cash & short-term investments per share (Finnhub)
Book Value / Share$31.57
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$38.27M
Total debt obligations (short + long term)
Cash & Equiv.$4.54B
Cash and short-term investments
Net Debt$-4.50BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$6.34B
Shareholders' equity (book value)
Asset / Liability5.15xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$22.92B
Current Market Capitalization
Beta0.78B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Incyte Genomics Inc (INCY)
Incyte Genomics Inc meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 10.93 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Incyte Genomics Inc posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 90/100, INCY trades near the cheapest end of its own historical range (P/E 14.2).
- Return on equity of 25.4% is well above the market average.
See how INCY ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all INCY moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 111.28 | +2.45% | 2.28 |
| Oct 14 | After-hours | 111.00 | +2.19% | 2.10 |
| Oct 12 | After-hours | 109.00 | -3.36% | -2.05 |
| Oct 1 | Regular | 117.42 | -3.24% | -2.11 |
Frequently Asked Questions about INCY
What is the current Incyte Genomics Inc (INCY) stock price?
INCY is trading at $113.07 at the last market close, down 0.18% on the session. PreMarketPrice tracks INCY pre-market, intraday and after-hours prices.
Is INCY stock a buy right now?
PreMarketPrice's quantitative model rates Incyte Genomics Inc's financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is INCY stock overvalued?
Incyte Genomics Inc trades at a trailing P/E of 14.2 and our valuation score rates it 90/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Incyte Genomics Inc report earnings?
No confirmed earnings date is currently scheduled for INCY. The Earnings section lists recent reports and updates as dates are announced.
What sector does Incyte Genomics Inc operate in?
Incyte Genomics Inc operates in the Healthcare sector, within the Services-Commercial Physical & Biological Research industry. The Related Stocks section lists sector peers for comparison.
What does Incyte Genomics Inc do?
Incyte focuses on the discovery and development of small-molecule drugs.
About Incyte Genomics Inc (INCY) Stock
Incyte Genomics Inc (INCY) is a US-listed stock operating in the Healthcare sector, specifically the Services-Commercial Physical & Biological Research industry. As of the latest update, Incyte Genomics Inc is trading at $113.07, down 0.18% on the day with a market capitalization of $22.9 billion. The financial health score for INCY is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for INCY stock.
INCY Stock Analysis & Key Metrics
On PreMarketPrice, you can track Incyte Genomics Inc (INCY) across multiple dimensions:
- Pre-market price & movement: Real-time INCY stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for INCY with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Incyte Genomics Inc across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for INCY.
- Sector peers: Compare INCY against 5 other healthcare stocks on key financial metrics.
Is INCY a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Incyte Genomics Inc (INCY) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Incyte Genomics Inc (INCY) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.